Related Experiment Video
Updated: Jun 6, 2025
04:47
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
Published on: October 27, 2023
895
Progress in targeted therapy for ankylosing spondylitis: A review
Jiapeng Wang1, Wang Lou2, Yingnan Li3
1Department of Orthopedics, Jilin Province FAW General Hospital, Changchun City, Jilin Province, China.
Medicine
|November 29, 2024
Summary
Ankylosing spondylitis (AS) treatment has advanced with biological agents, offering improved safety and efficacy over traditional drugs. This review evaluates targeted therapies for AS, providing insights for standardized clinical management.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Ankylosing spondylitis (AS) is a chronic inflammatory condition affecting the axial skeleton and entheses.
- Traditional treatments like NSAIDs and DMARDs present challenges in tolerance and effectiveness.
- Biological agents have revolutionized AS management due to their safety and efficacy.
Purpose of the Study:
- To systematically review the global landscape of targeted therapies for AS.
- To analyze the benefits and drawbacks of various biological agents used in AS treatment.
- To offer an objective evaluation of current targeted therapy approaches for AS.
Main Methods:
- Systematic literature review of targeted therapies for ankylosing spondylitis.
- Comparative analysis of different classes of biological agents.
- Evaluation of clinical data on safety, efficacy, and tolerance.
Main Results:
- Biological agents represent a significant advancement in AS treatment.
- Different biological agents exhibit varying profiles of advantages and disadvantages.
- Current targeted therapies offer improved outcomes compared to traditional approaches.
Conclusions:
- Targeted biological therapies are now a mainstay in AS management.
- Understanding the nuances of different agents is crucial for optimal patient care.
- This review provides a new perspective for standardized clinical treatment of AS.
Related Concept Videos
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:29Inflammatory Bowel Disease IV: Pharmacological Management
113
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
113
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
01:29Drugs for Treatment of Ulcerative Colitis in IBD
120
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
120
01:19Antiasthma Drugs: Leukotriene Modifiers
245
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
245